title: The effect of cyclosporine A (Restasis) on recovery of visual acuity following LASIK.
abstract: To compare the recovery of uncorrected visual acuity (UCVA) following LASIK in patients treated with topical cyclosporine A 0.05% and patients treated with a standard postoperative regimen.
  
  
  
  In this single-center, open-label, retrospective study, a standard refractive workup was performed in 45 patients (85 eyes) who underwent LASIK and did not have preexisting dry eye. In 36 eyes, a standard postoperative eye drop regimen was followed, and in 49 eyes, cyclosporine A 0.05% was added to the standard regimen for 12 weeks. Uncorrected visual acuity was measured 1 week and 1 and 3 months postoperatively.
  
  
  
  One week postoperatively, 22 (44.9%) eyes in the cyclosporine A group and 8 (22.2%) eyes in the standard treatment group had UCVA of 20/15. Cumulatively, 36 (73.5%) eyes in the cyclosporine A group and 24 (66.7%) eyes in the standard treatment group had UCVA of 20/20 or better. One month postoperatively, 37 (75.5%) in the cyclosporine A group and 23 (63.9%) eyes in the standard treatment group had UCVA of 20/20 or better. Three months postoperatively, 40 (81.6%) eyes in the cyclosporine A group and 25 (69.4%) eyes in the standard treatment group had UCVA of 20/20 or better. Mean UCVA in the cyclosporine A group showed statistically significant improvements compared with the standard treatment group.
  
  
  
  Cyclosporine A 0.05%, in the form of Restasis, may be an effective treatment for reducing the time needed for visual recovery after LASIK. Use of cyclosporine A was associated with overall better and faster recovery of UCVA.
authors.affiliation: Shiley Eye Center, University of California San Diego, 9415 Campus Point Dr, #0946, La Jolla, CA 92093-0946, USA.
authors.forename: Roxana
authors.initials: R
authors.lastname: Ursea
authors.forename: Tracy L
authors.initials: TL
authors.lastname: Purcell
authors.forename: Bryan U
authors.initials: BU
authors.lastname: Tan
authors.forename: Aniruddha
authors.initials: A
authors.lastname: Nalgirkar
authors.forename: Mario E
authors.initials: ME
authors.lastname: Lovaton
authors.forename: Michael R
authors.initials: MR
authors.lastname: Ehrenhaus
authors.forename: David J
authors.initials: DJ
authors.lastname: Schanzlin
mesh_terms: D000287:Administration, Topical; D000328:Adult; D000368:Aged; D000900:Anti-Bacterial Agents / Q000008:administration & dosage; D001251:Astigmatism / Q000601:surgery; D016572:Cyclosporine / Q000008:administration & dosage*; D004359:Drug Therapy, Combination; D005260:Female; D024841:Fluoroquinolones / Q000008:administration & dosage; D000077734:Gatifloxacin; D005938:Glucocorticoids / Q000008:administration & dosage; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage*; D020731:Keratomileusis, Laser In Situ; D054018:Lasers, Excimer; D008297:Male; D008875:Middle Aged; D009216:Myopia / Q000601:surgery; D011239:Prednisolone / Q000008:administration & dosage / Q000031:analogs & derivatives; D020127:Recovery of Function / Q000187:drug effects; D012189:Retrospective Studies; D014792:Visual Acuity / Q000187:drug effects*
chemical_list: D000900:Anti-Bacterial Agents; D024841:Fluoroquinolones; D005938:Glucocorticoids; D007166:Immunosuppressive Agents; D016572:Cyclosporine; C009935:prednisolone acetate; D011239:Prednisolone; D000077734:Gatifloxacin